PACTR201702001930102招募中未知
PCL management
orthopedic department0 个研究点目标入组 20 人开始时间: 2016年12月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Year(s) 至 50 Year(s)（—）
- 性别
- All
入选标准
- •1-Patient with displaced PCL tibial avulsion fracture >2 mm
- •2-Patients with isolated PCL avulsion
- •3-Patients with acute PCL avulsion less than 6 weeks
排除标准
- •1-Associated ligamentus injury
- •2-Old PCL avulsion more than 6 weeks
- •3-presence of joint arthritis
- •4-presence of joint infection
研究者
相似试验
进行中（未招募）
1 期
Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.o medical conditionCTIS2023-506416-41-00Tecnimede-Sociedade Tecnico-Medicinal S.A.16
进行中（未招募）
1 期
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy SubjectsAdvanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation., Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine in adults., Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10014743Term: Endometrial carcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10007476Term: Carcinoma thyroid Class: 10029104CTIS2022-501327-25-00Bluepharma Industria Farmaceutica S.A.36
进行中（未招募）
1 期
Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditionso medical condition.CTIS2023-509808-15-00Pharmaplot P.C.12
进行中（未招募）
1 期
Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjectso medical condition.CTIS2023-504901-34-00Synthon Chile LTDA.30
进行中（未招募）
1 期
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphomaewly diagnosed aggressive B-cell lymphoma (a-BCL)MedDRA version: 20.1Level: LLTClassification code: 10080217Term: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10023699Term: Large B-cell lymphoma subtype primary mediastinal (Thymic) large B-cell lymphoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065863Term: Anaplastic large-cell lymphoma primary cutaneous type Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10071977Term: Anaplastic lymphoma kinase gene mutation Class: 100000004850CTIS2023-506094-35-00Celgene Corp.174